• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for palliation of painful spinal metastases. NICE interventional procedures guidance 758
2004     HAYES, Inc. Radiofrequency ablation for primary and metastatic cancers of the liver
2009     HAYES, Inc. Radiofrequency ablation for renal tumors
2017     HAYES, Inc. Radiofrequency ablation for sacroiliac joint denervation for chronic low back pain
2012     HAYES, Inc. Radiofrequency ablation for sacroiliac joint pain
2015     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma. NICE interventional procedures guidance 539
2016     Technology Assessment Unit of the McGill University Health Centre (MUHC) Radiofrequency ablation for the treatment of Barrett's esophagus with high-grade and lowgrade dysplasia: an update
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Radiofrequency ablation for treating nasal hypertrophy of the inferior turbinates
2009     Technology Assessment Unit of the McGill University Health Centre (MUHC) Radiofrequency ablation for treatment of Barrett's esophagus: A systematic review and cost analysis
2004     HAYES, Inc. Radiofrequency ablation for trigeminal neuralgia
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Radiofrequency ablation in the treatment of kidney cancer
2006     Norwegian Knowledge Centre for the Health Services (NOKC) Radiofrequency ablation in treatment of atrial fibrillation
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Radiofrequency ablation of excess tongue tissue
2003     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation of hepatocellular carcinoma. NICE interventional procedures guidance 2
2003     Medical Services Advisory Committee (MSAC) Radiofrequency ablation of liver tumours
2006     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Radiofrequency ablation of liver tumours (update and re-appraisal): a systematic review. Report no. 56
2010     Blue Cross Blue Shield Association (BCBS) Radiofrequency ablation of nondysplastic or low-grade dysplastic barrett's esophagus
2010     Blue Cross Blue Shield Association (BCBS) Radiofrequency ablation of nondysplastic or low-grade dysplastic barrett's esophagus
2010     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Radiofrequency ablation of renal tumours
2005     Andalusian Health Technology Assessment Area (AETSA) Radiofrequency ablation of solid tumours
2011     HAYES, Inc. Radiofrequency ablation of the pulmonary veins for the treatment of atrial fibrillation
2008     HAYES, Inc. Radiofrequency ablation of the pulmonary veins for the treatment of atrial fibrillation
2014     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation of the soft palate for snoring. NICE interventional procedures guidance 476
2003     Blue Cross Blue Shield Association (BCBS) Radiofrequency ablation of unresectable hepatic tumors
2003     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation of varicose veins. NICE interventional procedures guidance 8
2001     HAYES, Inc. Radiofrequency catheter ablation
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Radiofrequency catheter ablation 64 electrode basket catheter
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Radiofrequency catheter ablation for cardiac arrhythmias: a clinical and economic review
2008     Blue Cross Blue Shield Association (BCBS) Radiofrequency catheter ablation of the pulmonary veins for treatment of atrial fibrillation
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Radiofrequency catheter ablation technique in atrial fibrillation
2012     National Institute for Health and Care Excellence (NICE) Radiofrequency cold ablation for respiratory papillomatosis. NICE interventional procedures guidance 434
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for sacroiliac and facet joint pain
1997     Health Council of the Netherlands Gezondheidsraad (GR) Radiofrequency electromagnetic fields (300 Hz - 300 GHz)
2004     HAYES, Inc. Radiofrequency endometrial ablation for menorrhagia secondary to dysfunctional uterine bleeding
2017     HAYES, Inc. Radiofrequency nerve ablation for treatment of plantar fasciitis
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Radiofrequency neurotomy for lumber pain
2012     Malaysian Health Technology Assessment (MaHTAS) Radiofrequency neurotomy of genicular nerve of both knees
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Radiofrequency techniques for the management of lumbar discopathy (discal nucleoplasty, percutaneous thermocoagulation, electrothermal annuloplasty)
2014     National Institute for Health and Care Excellence (NICE) Radiofrequency tissue reduction for turbinate hypertrophy. NICE interventional procedures guidance 495
2006     HAYES, Inc. Radiofrequency tissue volume reduction (RFTVR) for the treatment of upper airway obstruction
2007     HAYES, Inc. Radiofrequency tissue volume reduction for the treatment of upper airway obstruction
2017     National Institute for Health and Care Excellence (NICE) Radiofrequency treatment for haemorrhoids. NICE interventional procedures guidance 589
1999     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiofrequency treatment for liver and osseous metastasis (systematic review, expert panel)
2004     National Institute for Health and Care Excellence (NICE) Radiofrequency valvotomy for pulmonary atresia. NICE interventional procedures guidance 95
2000     HAYES, Inc. Radiofrequency volumetric tissue reduction for the treatment of upper airway obstruction
2007     National Institute for Health and Care Excellence (NICE) Radiofrequency-assisted liver resection. NICE interventional procedures guidance 211
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2013     HAYES, Inc. Radioiodinated metaiodobenzylguanidine (131I-MIBG) targeted radiation therapy for refractory or relapsed neuroblastoma
2003     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiological bucky tables with a CCD camera - systematic review, primary research, expert panel
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2001     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radionuclide therapy- systematic review, expert panel
1997     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiosurgery (systematic review, working group, expert panel)
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Radiosurgery in the treatment of malignant melanoma
2004     National Institute for Health and Care Excellence (NICE) Radiotherapy for age-related macular degeneration. NICE interventional procedures guidance 49
2003     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy for cancer
1999     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Radiotherapy in bone metastasis - primary research
1996     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy in Sweden [2 vols.]
2014     Agency for Healthcare Research and Quality (AHRQ) Radiotherapy treatments for head and neck cancer update
2014     Medical Services Advisory Committee (MSAC) Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases
2016     National Institute for Health and Care Excellence (NICE) Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2014     NIHR Health Technology Assessment programme Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
2017     HAYES, Inc. Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: a systematic review of efficacy and safety evidence
1999     ECRI Raloxifene, a selective estrogen receptor modulator [SERM] for prevention of postmenopausal osteoporosis
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ramipril 2.5 mg/5 ml oral solution
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for hepatocellular cancer – second line
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for metastatic colorectal cancer – second line
2016     National Institute for Health and Care Excellence (NICE) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016     National Institute for Health and Care Excellence (NICE) Ramucirumab for treating advanced gastric cancer or gastrooesophageal junction adenocarcinoma previously treated with chemotherapy. NICE technology appraisal guidance 378
2019     National Institute for Health and Care Excellence (NICE) Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal). NICE technology appraisal guidance 609
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab in combination with paclitaxel for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab monotherapy for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma – after prior chemotherapy
2020     National Institute for Health and Care Excellence (NICE) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2013     NIHR Health Technology Assessment programme Randomised Assessment of Treatment using Panel Assay of Cardiac markers - Contemporary Biomarker Evaluation (RATPAC CBE)
2006     NIHR Health Technology Assessment programme Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial)
2024     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2005     NIHR Health Technology Assessment programme Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year olds
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2000     NIHR Health Technology Assessment programme Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2005     NIHR Health Technology Assessment programme Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis
2009     NIHR Health Technology Assessment programme Randomised controlled trial of the use of the three dressing preparations in the management of chronic ulceration of the foot in diabetes